Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis.

Publication date: Aug 09, 2020

Melanoma antigen gene A2 (MAGE-A2) is one of the most cancer-testis antigens overexpressed in various types of cancers. Silencing the MAGE-A2 expression inhibited the proliferation of prostate cancer (PCa) cells and increased the chemosensitivity. However, the expression pattern of MAGE-A2 in PCa tissue samples and its prognostic and therapeutic values for PCa patients is still unclear.

In this study, for the first time, the staining pattern and clinical significance of MAGE-A2 were evaluated in 166 paraffin-embedded prostate tissues, including 148 cases of PCa and 18 cases of high-grade prostatic intraepithelial neoplasia (HPIN), by immunohistochemical analysis.

The simultaneous expression of both nuclear and cytoplasmic patterns of MAGE-A2 with different staining intensities was observed among studied cases. Increased expression of MAGE-A2 was significantly found in PCa tissues compared to HPIN cases (P

Taken together, cytoplasmic expression of MAGE-A2 was inversely proportional to the malignant grade and duration of recurrence of the disease in patients with PCa.

Concepts Keywords
Antigen Cancers
Antigens A2 cancer
Cancer Histopathology
Correlation Intraepithelial neoplasia
DFS Lesion
Gleason Score Prostate cancer
Immunohistochemical A2
Malignant Clinical medicine
Multivariate Analysis


Type Source Name
disease MESH tumor
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH prostate cancer
pathway KEGG Prostate cancer
drug DRUGBANK Pidolic Acid
disease MESH prostatic intraepithelial neoplasia
disease MESH Gleason score
disease MESH recurrence

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *